The FDA has approved two new drugs, Pfizer’s Selzentry (maraviroc) and Merck’s Isentress (raltegravir), for HIV that’s resistant to other meds. The newcomers hit fresh viral targets—Selzentry blocks a protein (CCR5) on immune cells and prevents HIV entry; Merck’s integrase inhibitor halts HIV’s hijacking of CD4 cells’ DNA. Both worked well in studies, especially when combined with other meds to which HIV is still sensitive. Experts expect even better things for treatment veterans using the two new drugs together. For more info, check out